APAC Much of the global pharma industry is talking about disruption, but Brendan Shaw, founder of Shawview Consulting and adjunct professor at the University of Sydney, has found a different mood in Asia Pacific: optimism. With Asia now accounting for about 43 percent of the global innovative pipeline and Western pharma…
China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Simcere Pharmaceutical expanding Greater China rights for Lynk’s JAK1 inhibitor zepuxitinib and Fresenius’ 10-year biosimilar collaboration with WuXi Biologics covering 37 candidates. Other updates feature AbbVie’s $757M migraine licensing deal with Brise, Minghui’s $440M Japan agreement with ASKA for…
Korea We are actively seeking opportunities to export our medicines to markets around the world Jae-young Lee took the helm of Bukwang Pharmaceuticals in 2024, inheriting a business undergoing serious challenges and with little room for complacency. Two years on, the company is back in profit, pursuing an ambitious growth target…
Europe There is no reason why patients with common diseases should have access to improved second- or third-generation treatments, while those living with rare diseases do not Europe helped pioneer rare disease innovation, yet the policies and research environment that once set it apart are increasingly being tested. Dr Soraya Bekkali,…
Korea HyeSook (Aviva) Park, country head of contract research organisation CMIC’s Korean affiliate, reflects on eight years spent repositioning the affiliate around complex, early-phase studies as client needs became more sophisticated. She discusses the changing expectations of licensing partners, the impact of a Japanese government grant programme recently opened to overseas…
USA A single pivotal trial can cost up to USD 150 million. A biosimilar efficacy study can take two to three years. A cell or gene therapy batch can be one patient’s only treatment. In 2026, along with several major personnel changes, the FDA moved to ease all three of these…
Hong Kong Hong Kong recently announced its first-ever Five-Year Plan, the latest sign of closer alignment with mainland China. With a clearer roadmap to 2030, what are the implications for biopharma? A First FYP Even since returning to Chinese control in 1997, Hong Kong has maintained its role as a trading…
Spain With a huge investment from AstraZeneca at its core, can the Spanish city of Barcelona really now rival more established European life sciences ecosystems? Back in 2023, Barcelona was a somewhat surprising choice for AstraZeneca’s new global R&D hub. The Catalan capital, Spain’s second largest city, lacks both the…
China Like most founders, my dream is to bring one of our own drugs to market and see patients genuinely benefit from our inventions Built on deep expertise in oligonucleotide chemistry, Leaderna Therapeutics is advancing a new generation of siRNA medicines for chronic diseases, with programmes spanning hypertension, dyslipidaemia and obesity.…
China Strong efficacy data attracts collaborators, but confidence shaken by other companies’ weaker results holds the whole field back Regend Therapeutics was founded in 2015 by Dr Ting Zhang and her husband, Professor Wei Zuo, to move stem cell research out of the lab and into patients. The company went on…
Germany Germany is one of Takeda’s largest markets, a major manufacturing base and an important clinical research location, yet its long-standing reputation for rapid access to innovation is coming under pressure. GM Germany Dr Ingeborg Borgheim discusses how Takeda is preparing its German operations for a new generation of launches, where…
India Ajay Mahipal of India-focused healthcare impact and venture capital investment platform HealthKois argues that India’s life-sciences ecosystem is approaching an inflection point. Having built its reputation on manufacturing scale, the country now has a narrow window to build the clinical-development capabilities needed to originate and test novel therapies itself. India…
See our Cookie Privacy Policy Here